MedTrace Logo

A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

NCT07011043 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-03-27

No results posted yet for this study

Summary

The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.

Conditions

Interventions

DRUG

Budoprutug

Single IV dose of study product on Day 1 of study

Sponsors & Collaborators

  • Climb Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Study Director · Climb Bio, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-10
Primary Completion
2027-04-30
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Georgia
  • Greece
  • Puerto Rico
  • Romania
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07011043 on ClinicalTrials.gov